Johnson & Johnson operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Johnson & Johnson with three other
major healthcare and pharmaceutical companies:
Bristol-Myers Squibb Company
sales of $19.43 billion
of which 100%
Baxter International Inc.
of which 62%
was Hospital Products), and
based in Switzerland
(48.83 billion Swiss Francs [US$50.76 billion]
of which 66%
was Innovative Medicines).
During the year ended December of 2016, sales at
Johnson & Johnson were $71.89 billion.
increase of 2.6%
versus 2015, when the company's sales were $70.08 billion.
Despite this increase, sales are still
below the level achieved in 2014, when Johnson & Johnson
reported sales of $74.34 billion.
Sales of Pharmaceutical saw an increase
that was more than double the company's growth rate: sales were up
6.5% in 2016, from
$31.43 billion to $33.46 billion.
Not all segments of Johnson & Johnson experienced an increase in sales in 2016:
sales of Consumer fell 1.5% to $13.31 billion.
Johnson & Johnson also experienced decreases in sales in
Medical Devices and Diagnostics (down 0.1% to $25.12 billion)